Defining immune-active mechanisms of PDL1V in translational ADC development
Abstract
“Our observation of synergistic antitumor activity at multiple nonclinical doses supports that PDL1V allows the functional activation and trafficking of PD-L1-positive cytotoxic immune cells within a wide therapeutic window.”Lauren Coyle (Launch Commissioning Editor, Bioconjugate Insights) speaks with Megan Atkins (Senior Scientist, Translational Pharmacology, Pfizer) about advancing PDL1V from non-clinical characterization to pivotal trials, and how deeper immune profiling is reshaping the future of immune-active ADCs.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Monoclonal and Polyclonal Antibodies Research
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Bioconjugation Insights
- Volume
- 1
- Issue
- 1
- Pages
- 1–5–1–5
- Publication date
- 19 January 2026
- Language
- EN